EICHORPublic-registry site landscape for NCT06637423, “A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)”, a Non-Muscle Invasive Bladder Cancer study sponsored by Merck Sharp & Dohme LLC. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT06637423 (registry record) |
| Study title | A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) |
| Official title | A Phase 1/2 Open-label Clinical Study to Evaluate the Safety and Efficacy of Intravesical Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (NMIBC) |
| Sponsor | Merck Sharp & Dohme LLC |
| Condition(s) | Non-Muscle Invasive Bladder Cancer |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 13 |
| Intervention(s) | Sacituzumab tirumotecan, Rescue medication, Supportive care measures |
| Site countries | United States, Canada, France, Netherlands, Spain, United Kingdom |
Patient-friendly overview of this study: eichor.com/study/NCT06637423.
Eichor generates a preliminary site-risk snapshot for NCT06637423 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
More from Merck Sharp & Dohme LLC
← Eichor home · All tracked trials · Non-Muscle Invasive Bladder Cancer studies · Weekly briefs
